FY2027 ICD-10-CM reference
E85: Amyloidosis
By the HCC Buddy Coding Team
The official ICD-10-CM descriptor is Amyloidosis. The FY2027 annual edition starts October 1, 2026. Check the edition that applies to the encounter or inpatient discharge, including any April update.
Nonbillable heading. Verified against the official FY2027 order file.
Oct to Dec 2026, PY2027
CMS-HCC V28
Not applicableCMS-HCC V24
Not applicableESRD
Not applicableRxHCC
Not applicablePACE (CMS-HCC V22 component)
Not applicablePACE ESRD (ESRD V21 component)
Not applicablePACE RxHCC (2018/2019 component)
Not applicableJan to Sep 2027, PY2028
CMS-HCC V28
Not applicableCMS-HCC V24
Not applicableESRD
Not applicableRxHCC
Not applicablePACE (CMS-HCC V22 component)
Not applicablePACE ESRD (ESRD V21 component)
Not applicablePACE RxHCC component
Not applicableOct to Dec 2026, BY2026
HHS-HCC
Not applicableJan to Sep 2027, BY2027
HHS-HCC
Not applicableMore specific FY2027 codes
- E85.0: Non-neuropathic heredofamilial amyloidosisBillable code
- E85.1: Neuropathic heredofamilial amyloidosisBillable code
- E85.2: Heredofamilial amyloidosis, unspecifiedBillable code
- E85.3: Secondary systemic amyloidosisBillable code
- E85.4: Organ-limited amyloidosisBillable code
- E85.8: Other amyloidosisNonbillable heading
- E85.9: Amyloidosis, unspecifiedBillable code
FY2027 Tabular instructions
Instructions below include applicable chapter, section and parent-code notes. Each note identifies where it appears in the official source.
Instructional note
All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.
Source: E00-E89 (chapter, inherited).
Excludes1
transitory endocrine and metabolic disorders specific to newborn (P70-P74)
Source: E00-E89 (chapter, inherited).
Excludes1
androgen insensitivity syndrome (E34.5-)
Source: E70-E88 (section, inherited).
Excludes1
congenital adrenal hyperplasia (E25.0)
Source: E70-E88 (section, inherited).
Excludes1
hemolytic anemias attributable to enzyme disorders (D55.-)
Source: E70-E88 (section, inherited).
Excludes1
Marfan syndrome (Q87.4-)
Source: E70-E88 (section, inherited).
Excludes1
5-alpha-reductase deficiency (E29.1)
Source: E70-E88 (section, inherited).
Excludes2
Ehlers-Danlos syndromes (Q79.6-)
Source: E70-E88 (section, inherited).
Excludes2
Alzheimer's disease (G30.0-)
Source: E85 (category, direct).
Compare the FY2027 additions, removals and billable-status changes
What does E85 mean in FY2027?
The official ICD-10-CM descriptor is Amyloidosis. The FY2027 annual edition starts October 1, 2026. Check the edition that applies to the encounter or inpatient discharge, including any April update.
Is E85 billable in FY2027?
The FY2027 order file marks E85 as a nonbillable heading. Select a complete billable child code.
Does E85 map to an HCC?
Risk-model mapping is not applicable to this nonbillable heading. Check a complete billable child code.
Source: CMS FY2027 ICD-10-CM order file. Payment model: CMS CY 2027 Rate Announcement. Read the FY2027 Official Guidelines.
Review the FY2026 April edition
